Login:
 
Saul P. Azithromycin beneficial in nonsmoking COPD patients who suffer exacerbations. Practitioner November/December 2022;266(1863):8-9

Azithromycin beneficial in nonsmoking COPD patients who suffer exacerbations

20 Dec 2022Registered users

Long-term azithromycin confers a net benefit in COPD patients who are former smokers with a recent history of exacerbations, a model-based benefit-harm analysis has shown. The benefit is likely to be larger in those patients who suffer frequent exacerbations, the study found.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.